Pharmaceuticals

Addressing unmet needs with LP-284 for relapsed/refractory lymphoma and solid tumors

bexib
By bexib 0 Min Read

In this Pharmaceutical Executive Video Interview, Panna Sharma, CEO of Lantern Pharma, discusses how LP-284 uniquely addresses unmet needs compared to existing and emerging therapies for relapsed/refractory lymphoma and solid tumors. I will explain how it is compatible.

You Might Also Like

Despite the powerful computing power, AI’s role in pharma remains plagued by challenges

2024 Pharm Exec Top 50 Companies

FDA Approves Merz Aesthetics’ Xeomin for Simultaneous Treatment of Upper Facial Wrinkles

Yvonne Greenstreet: Answer the phone

Moderna Receives $176 Million Biomedical Advanced Research and Development Authority Award to Advance Development of mRNA-Based Influenza Vaccine

Share This Article
Previous Article Closet Full of Treasures? Here’s How to Sell Vintage Clothing (2024)
Next Article 2024 RealAgristudies Hockey Playoff Survey Results – RealAgriculture
Leave a Comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Stay Connected

Latest News

Local SEO vs. Ecommerce SEO Puzzle
Retail & E-commerce
Singapore’s GFTN partners with Odisha to establish fintech hub
Fintech
Lazada and Peak3 bring digital insurance to over 5 million people in Southeast Asia
Fintech
Mandarin Oriental’s international chef praises Williams’ global credibility
Hospitality & Tourism